The standard treatment for patients with differentiated thyroid cancer (DTC) is a combination
of surgery, radioactive iodine (RAI), and long-term thyroid hormone–suppression therapy …

Thyroid cancer can be largely classified as well-differentiated, poorly differentiated,
medullary and anaplastic. Differentiated thyroid cancer (DTC) includes follicular and …

Thyroid cancer typically has a good outcome following standard treatments, which include
surgery, radioactive iodine ablation for differentiated tumours and treatment with thyrotropine …

Objective The treatment landscape for thyroid cancers has changed rapidly with the
availability of kinase inhibitors against VEGFR, BRAF, MEK, NTRK, and RET. We provide an …

Advanced thyroid cancer is not amenable to therapy with conventional cytotoxic
chemotherapy. However, newer advances in the understanding of the molecular …

Advanced thyroid carcinoma is an infrequent tumor entity with limited treatment possibilities
until recently. The extraordinary improvement in the comprehension of genetic and …

Thyroid carcinomas comprise distinct pathologic subtypes. However, advancements in
characterizing the molecular tumorigenesis of thyroid cancers have changed the treatment …

10 Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of
BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the …

Established systemic treatment options for advanced thyroid cancer include the multityrosine
kinase inhibitors lenvatinib and sorafenib for radioactive iodine refractory differentiated …

The treatment of advanced thyroid cancer has undergone rapid evolution in the last decade,
with multiple kinase inhibitor drug approvals for each subtype of thyroid cancer and a …